Last reviewed · How we verify
Placebo (ziltivekimab)
Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation.
Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation. Used for Cardiovascular disease with elevated inflammatory markers (Phase 3 development).
At a glance
| Generic name | Placebo (ziltivekimab) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | IL-6 inhibitor monoclonal antibody |
| Target | IL-6 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ziltivekimab binds to and neutralizes IL-6, a key pro-inflammatory cytokine involved in systemic inflammation and cardiovascular disease. By blocking IL-6, the drug aims to reduce inflammatory markers and potentially improve cardiovascular outcomes in patients with elevated inflammatory burden.
Approved indications
- Cardiovascular disease with elevated inflammatory markers (Phase 3 development)
Common side effects
- Infection
- Neutropenia
- Elevated liver enzymes
Key clinical trials
- Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction (PHASE3)
- A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack (PHASE3)
- A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (PHASE3)
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation (PHASE3)
- A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation (PHASE1)
- ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack (PHASE3)
- Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition (PHASE2)
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |